Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Aparicio is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2000 - 2002
UCLA-VA Greater Los AngelesResidency, Internal Medicine, 1997 - 2000
Autonomous University of Madrid Class of 1995
Certifications & Licensure
CA State Medical License 1999 - Present
FL State Medical License 2021 - Present
TX State Medical License 2006 - 2027
OK State Medical License 2020 - 2021
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
Clinical Trials
- Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer Start of enrollment: 2006 May 01
- Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma Start of enrollment: 2007 Oct 01
- Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2016 May 18
Publications & Presentations
PubMed
- Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers.Elavarasan Subramani, Patrick G Pilié, Rebecca Slack-Tidwell, Paul V Viscuse, Xianghong Kuang
Iscience. 2026-06-19 - 1 citationsIntegrating systemic therapy and metastasis-directed therapy in oligometastatic hormone-sensitive prostate cancer.Xiaolei Shi, Jarey H Wang, Brian F Chapin, Ana Aparicio, Sumit K Subudhi
Prostate Cancer and Prostatic Diseases. 2026-06-01 - Prostate-Specific Membrane Antigen Radioligand Therapy in Patients with Aggressive-Variant Prostate Cancer.Moein Moradpour, Abuzar Moradi Tuchayi, Surekha Yadav, Fei Jiang, Irene A Burger
Journal of Nuclear Medicine. 2026-05-01
Press Mentions
Subset of Men with Rare Prostate Cancer May Benefit from Immunotherapy Added to Chemotherapy and Targeted Maintenance TherapyMay 30th, 2025- MD Anderson Researchers Showcase Groundbreaking Multi-Cancer Studies at ASCOMay 23rd, 2025
- Paul Viscuse, MD, on Androgen-Indifferent Prostate CancersSeptember 8th, 2021
Grant Support
- Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)UNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
